Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02784106 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis
A Phase 2 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT02784106 is a Phase 2 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 65 participants.
The verdict
NCT02784106, a Phase 2 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the efficacy of M2951 in participants with rheumatoid arthritis (RA) currently treated with stable dose of methotrexate (MTX).
Interventions
- DRUG Placebo
- DRUG M2951
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2016-07-31 |
| Est. Completion | 2017-11-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02784106
The ClinicalTrials.gov registry entry for NCT02784106 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02784106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02784106 about?
NCT02784106 is a clinical study titled "Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis". M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the efficacy of M2951 in participants with rheumatoid arthritis (RA) currently treated with stable dose of methotrexate (MTX).
What is the current status of trial NCT02784106?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2016-07-31. Estimated completion is 2017-11-14.
What interventions are being tested in trial NCT02784106?
The interventions under investigation include: Placebo (DRUG), M2951 (DRUG).
Who is sponsoring clinical trial NCT02784106?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.